Q-omics provides the consensus-scored NUP210L profile across patient tissues and cancer cell-line models. NUP210L expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NUP210L is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, NUP210L RNA expression shows 14,260 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where NUP210L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP210L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP210L survival associations across molecular data types. NUP210L RNA expression shows survival associations in the most cancer types (18), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP210L RNA expression–survival associations across cancer types. High NUP210L expression shows unfavorable associations in UVM, ACC and KIRC, but favorable associations in LUAD, HNSC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NUP210L RNA expression.
This table summarizes NUP210L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NUP210L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP210L shows lower tumor expression in LUSC and KICH and higher tumor expression in LUAD, CHOL, BRCA and STAD. The LUAD box plot shows higher NUP210L RNA expression in tumor versus normal tissue (log2 FC = +0.427, t-test p < 0.001).
This table shows molecular features associated with NUP210L in patient tissues and cancer cell lines. In patient samples, NUP210L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUP210L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
